Estados Unidos · Bolsa y Finanzas · The Motley Fool

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Publicado por The Motley Fool · Estados Unidos hace 8 h

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

Leer el artículo completo en The Motley Fool Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)

También te puede interesar

Business Insider

I moved my family from Australia to New York City 12 years ago. It's led to some very expensive regrets.

China passenger vehicle retail market slumps 24% in September

Trump says he’s evaluating whether the U.S. should join Saudi Arabia’s fight against Iran-backed Houthi rebels in Yemen after fresh attacks on Riyadh

CFTC Draws the Line Between Prediction Markets and Gambling in New Rules

Petra Power looks to modernize energy for data centers and defense vehicles

Kasai, Klarity and 8 other baby names surging in America